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Abstract 
N-3-(1-Methylindol-3-yl)propan-N-(2,2,2-trichloroethoxysulfonyl)guanidine was synthesized 
from 3-formyl-1-methylindole in six steps and subjected to conditions intended to convert the 
side-chain into a 2-iminotetrahydropyrimidine- containing product, of relevance to a possible 
synthesis of the aplicyanins. An alternative reaction course was observed, resulting in the 
formation of a new tetracyclic system. 
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Introduction 
 
Recently, a new family of five antitumor agents, the aplicyanins, 1, was isolated from an 
Antarctic ascidian Aplidium cyaneum,1 for example aplicyanin A has R1=R2=R3=H, aplicyanin B 
has R1=Ac, R2=R3=H, and the most complex, aplicyanin F has R1=Ac, R2=OMe, R3=Br. 
Following our studies on the synthesis of a variety of heterocyclic marine natural products2 and 
derivatives3 we were attracted to the synthesis of such structures and describe here our initial 
model study aimed at constructing a 4-(indol-3-yl)tetrahydropyrimidine. Our plan was to 
construct the reduced pyrimidine unit, following the recent work by Du Bois et al.4 However, an 
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unexpected cyclization took place involving the indole unit and there was formed a fused 
tetracyclic structure, 2, an example of a previously unknown heterocyclic system. 
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 DuBois demonstrated the use of trichloroethoxysulfonamides in intermolecular benzylic C–
H insertion reactions,4b and further that trichloroethoxysulfonyl (Tces)- protected ureas and 
guanidines can be used for intramolecular insertions into benzylic and tertiary positions.4c The 
example which was of most relevance for our proposed synthesis is shown in Scheme 1 wherein 
a five-membered reduced imidazole 4 was constructed from precursor 3. Our thesis was that a 
comparable insertion into the indolylic position of a compound 5 would lead to 6 (Scheme 2). 
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Results and Discussion 
 
The construction of the cyclization precursor 5 began with 3-formyl-1-methylindole, 7, which 
was brought into a Wittig reaction with commercially available 8, giving the unsaturated 
aldehyde 9.5 Catalytic reduction of compound 9 saturated the double bond and also converted the 
aldehyde into an alcohol, producing the N-methyl homotryptophol 10 6 (Scheme 3). 
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Scheme 3 
 
 Conversion of the alcoholic function into a primary amine was achieved in three steps, the 
last two in one pot. The alcohol was converted efficiently into a mesylate 11, and the nitrogen 
introduced by displacement using the anion of diformamide, hydrolysis then liberating the N-
methyl homotryptamine, 12, in an overall 92% yield for the last two steps (Scheme 4). 
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Scheme 4 
 
 Finally, the Tces- protected guanidine unit in 5 was constructed by reaction of the primary 
amine with the isothiourea 13, again following the work of Du Bois4c (Scheme 5). 
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 We were now ready to attempt the side-chain cyclization hoping for the formation of the 
tetrahydropyrimidine, 6. Exposure of 5 to the conditions described by Du Bois produced, in 25% 
yield, a product that we deduce has structure 2 (Scheme 6). Initially, we were surprised to 
observe the presence of three CH2 groups in the product, instead of the two expected for a 
tetrahydropyrimidine derivative. Thus, in addition to the benzene ring signals, there were signals 
for the (CH2)3 unit, but there was no indole α-proton signal in the 1H NMR spectrum, but instead 
a singlet signal at 5.34 was observed for H-6a (see Scheme 7 and Table 1). A detailed HMBC 
and NOESY study revealed correlations (Scheme 7) that support the proposed structure 2. The 
H-6a shows HMBC long distance correlations (C1, C5, N-Me, C7a, and C11a), as well as NOE 
signals (H1, H6, and N-Me) with at least one atom of each ring, which was very useful for the 
assignment of the structure and stereochemistry of 2.   In particular, the NOE effect between H6a 
and one of the protons on C1 established the cis- relationship shown in 2. Deprotection of 2 gave 
the corresponding N-hydrogen guanidine 14. 
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Table 1. NMR data for 1,2,3,6,6a,7-hexahydro-7-methyl-5-(N-(2,2,2-trichloroethoxy-
sulfonyl)imino)-1H-pyrrolo[1,2-c]imidazolo[5,4-b]indole (2) 
C /H 
number δH (multiplicity, number of H) δC HMBC 
NOESY 
1 1.99-2.07 (m, 1H); 2.31-2.41 (m, 1H) 34.8 (t) H1-C3 
H1-C6a 
H1-C11a 
H6a 
2 2.16-2.25 (m, 1H); 2.31-2.41 (m, 1H) 25.4 (t)  H3 
3 3.33-3.38  (m, 1H); 3.89-3.95  (m, 1H) 45.1 (t) H3-C1 
H3-C5 
H2, H3 
5 - 160.9 (s)  - 
6 7.55 (bs, 1H)  H6-C5 
H6-C6a 
H6a, Me 
6a 5.34 (s, 1H) 84.7 (d) H6a-C1 
H6a-C5 
H6a-Me 
H6a-C7a 
H6a-C11a 
H1, H6, Me 
7a - 149.8 (s)  - 
8 
 
6.54 (d, 1H) 107.4 (d) H8-C10 
H8-C11a 
H9, Me 
9 7.24 (t, 1H) 130.5 (d) H9-C7a 
H9-C11 
H8, H10 
10 6.76 (t, 1H) 118.8 (d) H10-C8 
H10-C11a 
H9, H11 
11 
 
7.13 (d, 1H) 122.9 (d) H11-C7a 
H11-C9 
H10 
11a - 129.2 (s)  - 
11b - 29.7 (s) - - 
N-
SO3CH2CCl3 
4.60 (d, 1H); 4.65 (d, 1H) 78.3 (t) -  
-CCl3 - 94.1 (s)  - 
Me 2.94 (s, 3H) 32.7 (q) Me-C6a 
Me-C7a 
H6, H6a, H8 
 
Mechanism of the cyclization 
We have considered several mechanisms whereby the tetracycle 2 might be formed. One 
possibility, summarized in Scheme 8, is that the rhodium catalyst is not involved and that the 
conversion is initiated by activation of nitrogen by PhIOAc+ then electrophilic attack at the 
indole β position. We discounted this possibility on the grounds that when compound 5 was 
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exposed to PhI(OAc)2 and MgO without the rhodium catalyst, a very complex mixture was 
obtained, in which the tetracycle 2 could not be detected.  
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 We speculate that the rhodium-catalyzed oxidative cyclization of an indol-3-ylmethanol 
carbamate7 (Scheme 9, 15 → 16), which was postulated to involve nucleophilic attack of the 
indole on the nitrogen of a rhodium-nitrene complex, is a partial precedent for the present 
conversion. 
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 The analogy is not exact, as in the present case the nitrene nitrogen becomes attached to C2 
of the indole. However, it is possible that a similar mechanism could operate, perhaps by initial 
direct attack at indole C3 (→ 18), followed by migration (or equilibration) to C2 (Scheme 10, 18 
→ 19).  
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 A variant on this would involve attack of the indole on the metal, followed by reductive 
elimination. Such processes may be related to the palladium- and rhodium-catalyzed direct 
intermolecular arylations of indoles, which proceed via electrophilic metallation and involve 
C2/C3 equilibration.8,9 
 Finally, the mechanism could involve a nitrene formed from the primary amino group 
engaging in a cycloaddition with the indole double bond forming an aziridine 20. Intramolecular 
nucleophilic ring opening, as indicated in Scheme 11 would complete the process. This step 
would have to involve considerable SN1 character in the breaking of the C–N bond, to allow 
formation of the observed stereochemical outcome. 
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Experimental Section 
 
General Procedures. Reagents and solvents were purified according to Purification of 
Laboratory Chemicals, Armarego, W. and Chai C., Elsevier (2003).  Melting points (mp) were 
determined in a Büchi Melting Point B540 in open capillaries and are uncorrected. Automatic 
flash chromatography was carried out in an Isco Combiflash medium pressure liquid 
chromatograph with Redisep silica gel columns (47-60 µm), and C-18 reverse phase columns. A 
Branson ultrasound bath was used to perform sonication. 1H NMR and 13C NMR spectra were 
recorded on a Varian Mercury 400 MHz spectrometer and a Gemini 200 MHz spectrometer. 
Multiplicity of the carbons was assigned with DEPT and gHSQC experiments, although the 
usual abbreviations according to off-resonance decoupling are used: (s) singlet, (d) doublet, (t) 
triplet, and (q) quartet. The same abbreviations are used for the multiplicity of signals in H-NMR 
and also: (m) multiplet, (bs) broad singlet, (bt) broad triplet. Spectra were referenced to 
appropriate residual solvent peaks (d6-DMSO, or CDCl3). IR spectra were obtained on a Thermo 
Nicolet FT-IR spectrometer. HRMS were performed on a Bruker Autoflex high-resolution mass 
spectrometer by Unidad de Espectrometría de Masas (Universidad de Santiago de Compostela) 
and by Servei d’Espectrometria de Masses (Universitat de Barcelona). Microwave-assisted 
reactions were carried out in a CEM Discover microwave apparatus.  An automatic syringe 
pump was used as specified for controlled addition of some reactants. Reversed phase analytical 
HPLC was performed on a Waters Alliance separation module 2695 using a Waters Xterra MS 
C18 column (150 x 4.6 mm, 5 µm) and a Waters 996 PDA detector at 254 nm. 
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(E)-3-(1-Methylindol-3-yl)propenal (9). NaOEt (1.35 g, 18.8 mmol) was added to a suspension 
of 2-(1,3-dioxolan-2-yl)ethyltriphenylphosphonium bromide 8 (4.40 g, 10.1 mmol) in THF-
EtOH (99:1, 100 mL). The mixture was stirred at r.t. for 1 h during which time it turned yellow. 
Then, 3-formyl-1-methylindole 7 (1.0 g, 6.3 mmol) was added, and the mixture was stirred for 
72 h at reflux. The solvent was removed and the residue was dissolved in EtOAc, and washed 
with sat. NH4Cl then brine. The organic solution was dried over MgSO4 and solvent removed. 
The residue was digested with hexane. The hexane solution was collected and evaporated. The 
residue was purified by SiO2 flash chromatography. Elution with CH2Cl2 gave 9 (1.02 g, 71%) as 
a yellow oil. 1H NMR (CDCl3, 200 MHz) δ 3.85 (s, 3H); 6.74 (dd, J = 15.7, 7.9 Hz, 1H); 7.26-
7.37 (m, 3H); 7.38 (s, 1H); 7.65 (d, J = 15.7, 1H); 7.90 (dd, J = 7.9 and 2.3 Hz, 1H); 9.60 (d, J = 
7.9 Hz, 1H). MS (ESI) 186 (M+1, 100).  
3-(1-Methylindol-3-yl)propan-1-ol (10). Pd/C (10%) was added to a solution of 9 (2.2 g, 12.0 
mmol) in t-BuOH (100 mL). The suspension was purged with H2 and stirred for 16 h. The 
reaction mixture was filtered through a Celite pad, which was then washed with CH2Cl2. The 
solvent was removed under vacuum to provide compound 10 (quant. yield). 1H NMR (CDCl3, 
200 MHz) δ 1.42 (bs, 1H); 1.97 (m, 2H); 2.85 (t, J = 7.5 Hz, 2H); 3.72 (t, J = 6.5 Hz, 2H); 3.74 
(s, 3H, Me); 6.85 (s, 1H); 7.10 (t, J = 7.6 Hz, 1H); 7.18-7.27 (m, 2H); 7.60 (d, J = 8.0 Hz, 1H). 
13C NMR (CDCl3, 50.3 MHz) δ 21.3 (t); 32.6 (q); 33.2 (t); 62.7 (t); 109.1 (d); 114.3 (s); 118.5 
(d); 118.9 (d); 121.4 (d); 126.1 (d); 127.9 (s); 137.0 (s). MS (ESI) 190 (M+1, 100), 191 (M+2, 
16).  
3-(1-Methylindol-3-yl)prop-1-yl methanesulfonate (11). Mesyl chloride (299 µL, 3.9 mmol) 
was added to a solution of 10 (609.5 mg, 3.2 mmol), DMAP (39.3 mg, 0.3 mmol) and Et3N (449 
µL, 3.54 mmol) in CH2Cl2 (30 mL). The reaction mixture was stirred for 1 h at r.t. After this 
time, the solution was washed with sat. NH4Cl then brine. The organic solution was dried and 
evaporated to give 11 as a yellow oil (770 mg, 90%) which was used without further purification. 
1H NMR (CDCl3, 200 MHz) δ 2.14 (m, 2H); 2.90 (t, J = 7.2 Hz, 2H); 2.98 (s, 3H, Me); 3.75 (s, 
3H, Me); 4.27 (t, J = 6.3 Hz, 2H); 6.88 (s, 1H); 7.10 (dd, J = 6.7 and 1.5 Hz, 1H); 7.19-7.32 (m, 
3H); 7.56 (d, J = 7.8 Hz, 1H).  
3-(1-Methylindol-3-yl)propan-1-amine (12). A mixture of 11 (1.07 g, 4.0 mmol) and sodium 
diformylamide (0.57 g, 6.0 mmol) in dry DMF (30 mL) were stirred for 8 h at 50 ºC. The solvent 
was removed under reduced pressure. The crude material was dissolved in MeOH (30 mL) and 
heated at reflux for 2 h. After this time 1M HCl·MeOH (45 mL) was added and the solution was 
heated at reflux temperature for 3 h. Elimination of the solvent under vacuum afforded 12 (693 
mg, 92%) pure, as a yellow solid. 1H NMR (CDCl3, 400 MHz) δ 1.86-1.92 (m, 4H); 2.81-2.86 
(m, 4H); 3.73 (s, 3H, Me); 6.85 (s, 1H); 7.16 (t, J = 7.9 Hz, 1H); 7.27 (t, J = 7.9 Hz, 1H); 7.32 (d, 
J = 7.9 Hz, 1H); 7.65 (d, J = 7.9 Hz, 1H). 13C NMR (CDCl3, 100 MHz) δ 22.2 (t); 32.3 (q); 33.9 
(t); 41.7 (t); 108.9 (d); 114.5 (s); 118.3 (d); 118.8 (d); 121.2 (d); 125.8 (d); 127.7 (s); 136.8 (s). 
MS (ESI) 189 (M+1, 100), 190 (M+2, 15). 
N-3-(1-Methylindol-3-yl)propan-N-(2,2,2-trichloroethoxysulfonyl)guanidine (5). A thick-
walled tube was charged with S-methyl-N-(2,2,2-trichloroethoxysulfonyl)isothiourea 13 (267.7 
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mg, 0.9 mmol), 12 (167.1 mg, 0.9 mmol), 2.0 mL of H2O, and a magnetic stir bar. The vessel 
was sealed with a Teflon screw-cap and heated at 100 ºC for 4 h. After this time, the reaction 
mixture was cooled to r.t. and 5 mL of CH2Cl2 were added. The biphasic mixture was transferred 
to a separatory funnel, and partitioned between 10 mL CH2Cl2 and 10 mL H2O. The aqueous 
solution was extracted with CH2Cl2. The combined organic extracts were dried over MgSO4 and 
concentrated under reduced pressure. Purification by SiO2 chromatography with hexane-EtOAc 
(80:20 to 40:60) afforded the product 5 (247 mg, 63%) as a yellow oil. IR (film) ν 3460, 3358, 
2942, 2250, 1628, 1588, 1551, 1318, 1180, 1131, 1021, 742 cm-1. 1H NMR (CDCl3, 400 MHz) δ 
1.95 (bs, 2H, CH2); 2.80 (bt, 2H, CH2); 3.12 and 3.30 (2x bs, 2H, CH2); 3.72 (s, 3H, Me); 4.59 
(s, 2H); 5.90 (bs, 1H); 6.26 (bs, 1H); 6.53 (bs, 1H); 6.88 (s, 1H); 7.11 (t, J = 7.9 Hz, 1H); 7.26 (t, 
J = 7.9 Hz, 1H); 7.30 (d, J = 7.9 Hz, 1H); 7.57 (d, J = 7.9 Hz, 1H). 13C NMR (CDCl3, 50.3 MHz) 
δ 22.0 (t); 29.1 (t); 32.5 (q); 41.2 (t); 78.0 (t); 94.0 (s); 109.2 (d); 118.6 (2d); 121.5 (d); 126.4 (d); 
127.4 (s); 136.9 (s); 156.8 (s). MS (ESI) 441 (M+1, 96), 443 (M+3, 100), 444 (M+4, 12). HRMS 
m/z calcd. for C15H20Cl3N4O3S 441.0316, found 441.0316. 
1,2,3,6,6a,7-Hexahydro-7-methyl-5-(N-(2,2,2-trichloroethoxysulfonyl)imino)-1H-
pyrrolo[1,2-c]imidazolo[5,4-b]indole (2). A flame-dried 25 mL Schlenk flask was charged with 
5 (96.6 mg, 0.22 mmol), Rh2(esp)2 (3.3 mg, 4.4 µmol), PhI(OAc)2 (116.4 mg, 0.35 mmol), and 
MgO (22.5 mg, 0.55 mmol). The reaction vessel was closed with a rubber septum, the contents 
placed briefly under vacuum, and the flask then backfilled with Ar. This process was repeated 
two additional times prior to the addition of 2 mL of deoxygenated toluene. The resulting deep 
green suspension was heated at 40 °C and stirred for 16 h. After this time, the mixture was 
cooled to r.t., and the residue was purified by column chromatography over silica gel. Elution 
with hexane-EtOAc (from 75:25 to 65:35), afforded 2 (23 mg, 23%) as a yellow oil. IR (film) ν 
3367, 2925, 1786, 1584, 1498, 1179, 852 cm-1. 1H NMR (CDCl3, 400 MHz) δ 1.99-2.07 (m, 
1H); 2.16-2.25 (m, 1H); 2.31-2.41 (m, 2H); 2.94 (s, 3H); 3.33-3.38  (m, 1H); 3.89-3.95  (m, 1H); 
4.60 (d, J = 11.0 Hz, 1H); 4.65 (d, J = 11.0 Hz, 1H); 5.34 (s, 1H, CH); 6.54 (d, J = 7.5 Hz, 1H); 
6.76 (t, J = 7.5 Hz, 1H); 7.13 (d, J = 7.5 Hz, 1H); 7.24 (t, J = 7.5 Hz, 1H); 7.55 (bs, 1H, NH). 13C 
NMR (CDCl3, 100 MHz) δ 25.4 (t); 29.7 (s); 32.7 (q); 34.8 (t); 45.1 (t); 78.3 (t); 84.7 (d); 94.1 
(s); 107.4 (d); 118.8 (d); 122.9 (d); 129.2 (s); 130.5 (d); 149.8 (s); 160.9 (s). MS (ESI-TOF) 439 
(M+1, 84), 441 (M+3, 100). HRMS m/z calcd. for C15H18Cl3N4O3S 439.0165, found 439.0159. 
1,2,3,6,6a,7-Hexahydro-7-methyl-5-imino-1H-pyrrolo[1,2-c]imidazolo[5,4-b]indole (14). 
Compound 2 (22.6 mg, 0.05 mmol) was added to a suspension of powdered Zn (17.7 mg, 0.26 
mmol) in 1.5 mL of a 50:50 MeOH/AcOH solution. The mixture was stirred vigorously at 40 ºC 
for 16 h. The reaction was then cooled to r.t. and diluted with 1 mL of MeOH, and the contents 
filtered through a small pad of Celite with additional elution with MeOH. The combined filtrates 
were concentrated under reduced pressure and the residue was purified by reverse phase 
chromatography. Elution with H2O/MeCN (60:40 to 40:60) gave 14 as a white solid (3.4 mg, 
29%). 1H NMR (d6-DMSO, 400 MHz) δ 1.85-1.96 (m, 2H, CH2); 2.09-2.18 (m, 2H, CH2); 2.83 
(s, 3H, Me); 3.03-3.07 (m, 1H); 3.55-3.61 (m, 1H); 5.17 (s, 1H, CH); 5.74 (s, 1H); 6.48 (d, J = 
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7.9 Hz, 1H); 6.62 (t, J = 7.4 Hz, 1H); 7.08-7.15 (m, 2H); 8.14 (bs, 1H). MS (ESI-TOF) 229 
(M+1, 100). HRMS m/z calcd. for C13H17N4 229.1453, found 229.1455. 
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